SCHEMBL17452659

SCHEMBL17452659

CC(C)C(=O)c1cnn2c(CN(C)C)c(OCc3ccccc3)ccc12

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MCHR1 Q99705 2/20 0.39
▸ EGFR P00533 2/20 0.37
▸ TDP1 Q9NUW8 3/20 0.37
▸ MAPT P10636 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ PTGER1 P34995 1/20 0.36
▸ KDM4E B2RXH2 2/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ SRC P12931 1/20 0.36
▸ LRRK2 Q5S007 1/20 0.36
▸ ALKBH1 Q13686 1/20 0.35
▸ TRPM8 Q7Z2W7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17454378 0.88 MAPT (0.46) MEN1KMT2AMCHR1EGFRTDP1
SCHEMBL17437971 0.86 MEN1 (0.40) MEN1KMT2AMCHR1EGFRTDP1
SCHEMBL17452655 0.84 TDP1 (0.43) TDP1MAPTCYP2C9CYP2C19SMN1; SMN2
SCHEMBL17452658 0.80 XDH (0.41) TDP1MAPTCYP2C9CYP2C19SMN1; SMN2
SCHEMBL17452672 0.80 GRM2 (0.41) TDP1MAPTCYP2C9CYP2C19SMN1; SMN2
SCHEMBL17452656 0.79 ROCK2 (0.40) MEN1KMT2ATDP1KDM4EALDH1A1
SCHEMBL17437885 0.76 NOTUM (0.43) TDP1MAPTCYP2C9CYP2C19SMN1; SMN2
SCHEMBL17452634 0.73 ALKBH1 (0.43) L3MBTL1ALKBH1
SCHEMBL17452646 0.72 ROCK2 (0.37) —
SCHEMBL17454421 0.71 TDP1 (0.54) TDP1MAPTCYP2C9CYP2C19SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 — — US disclosed
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL MYERS SQUIBB CO (US) 2018-06-07 — — US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 — — US disclosed
US-9902702-B2 Spirocycloheptanes as inhibitors of rock BRISTOL-MYERS SQUIBB COMPANY (US) 2018-02-27 — — US disclosed
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK BRISTOL-MYERS SQUIBB COMPANY 2016-01-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155296-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 MEN1 363/4885KMT2A 2302/4885MCHR1 2455/4885
US-20160016914-A1 SPIROCYCLOHEPTANES AS INHIBITORS OF ROCK ROCK1, MYLK, ROCK2 MEN1 363/4885KMT2A 2302/4885MCHR1 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback